HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy
about
Chromatin immunoprecipitation to analyze DNA binding sites of HMGA2A covalent protein-DNA 5'-product adduct is generated following AP lyase activity of human ALKBH1 (AlkB homologue 1)High-Mobility Group A (HMGA) Proteins and Breast Cancer.Apurinic/apyrimidinic (AP) site recognition by the 5'-dRP/AP lyase in poly(ADP-ribose) polymerase-1 (PARP-1)Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers.3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice.High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugsHigh mobility group protein-mediated transcription requires DNA damage marker γ-H2AX.The Architectural Chromatin Factor High Mobility Group A1 Enhances DNA Ligase IV Activity Influencing DNA RepairCritical role of HMGA proteins in cancer cell chemoresistance.1,2,3,4-Diepoxybutane-induced DNA-protein cross-linking in human fibrosarcoma (HT1080) cells.Targeting DNA polymerase ß for therapeutic intervention.Mechanisms of therapeutic resistance in cancer (stem) cells with emphasis on thyroid cancer cells.Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression.Probing into the biological processes influenced by ESC factor and oncoprotein HMGA2 using iPSCs.Identification of a conserved 5'-dRP lyase activity in bacterial DNA repair ligase D and its potential role in base excision repair.HMGA2 plays an important role in Cr (VI)-induced autophagy.MiR-33b-5p sensitizes gastric cancer cells to chemotherapy drugs via inhibiting HMGA2 expression.HMGA2 inhibits apoptosis through interaction with ATR-CHK1 signaling complex in human cancer cells.Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.High Mobility Group A2 protects cancer cells against telomere dysfunction.Dovitinib enhances temozolomide efficacy in glioblastoma cells.Mesenchymal Tumorigenesis Driven by TSC2 Haploinsufficiency Requires HMGA2 and Is Independent of mTOR Pathway Activation.Cell-based high-throughput compound screening reveals functional interaction between oncofetal HMGA2 and topoisomerase I.Reactivity and Cross-Linking of 5'-Terminal Abasic Sites within DNA.Nanoscale Assembly of High-Mobility Group AT-Hook 2 Protein with DNA Replication Fork.
P2860
Q24300947-BD158558-978C-4C80-B6C5-912465FCEF23Q28288765-FE6FA4C3-EB39-4F6D-B9B6-9F3F4F7048A4Q34096006-CE7CA078-AD5E-4D8B-8306-A8D7FD4FE0A4Q34438595-6C8A4002-0190-4C74-BE3A-F4F5D35CA026Q34810805-17264165-DD58-4EE4-91B7-9460A2170B40Q35037403-7CFF98E1-A9F6-4F32-9ED1-727D3A9258B0Q35437204-B428FFEF-B852-4EED-BCEF-AFF4DF6B7409Q35823810-13AA9EE5-E1CF-40E7-A1B4-4995C8871C7FQ36159491-0CF6DDBC-4C86-4663-88E1-70EAC13D2D89Q36308084-93DDE11A-4F6F-4545-A60D-A834E07EF4BAQ36925937-FF76EC01-10E5-4718-8FBF-652C5307FADEQ37489149-D82DAE50-C0BF-4971-9555-92D117C625E0Q37676466-2F84CA4E-9ECC-483B-9F0A-EC0C42919DA9Q37970379-427F6106-56D6-444A-A08D-4EE0CF9D426AQ38497339-0D772C71-6C36-4C5A-87D0-2155CE9AC0B5Q38667954-872CCC2F-20A1-495D-AD4D-9499B8695560Q38782908-02FFA5DF-AFC2-40D5-8F15-2DA09051803DQ38823432-B5925C0E-2B40-41E6-B912-BD1FAE56A1D4Q39182492-EDA3BA8B-CE30-41B3-B4A6-570B6443B437Q39621410-B2E596A1-5EBE-4B23-9043-0A205269A366Q40073650-842E7811-E069-48C9-9EBA-3FCEDA150AA4Q40214485-353D4294-37EB-4395-BC6B-53BD0423A879Q41365464-9DC5EFB6-FC19-45F5-A859-5DD2B089E78EQ41881025-2A7F5AEA-8E5C-4444-8112-4553BEE10200Q46369057-CF80087B-C180-4905-864E-559110052E8AQ47270675-657A032C-F98E-495C-9547-F042A84ADC2A
P2860
HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
HMGA2 exhibits dRP/AP site cle ...... totoxicity during chemotherapy
@ast
HMGA2 exhibits dRP/AP site cle ...... totoxicity during chemotherapy
@en
HMGA2 exhibits dRP/AP site cle ...... totoxicity during chemotherapy
@en-gb
HMGA2 exhibits dRP/AP site cle ...... totoxicity during chemotherapy
@nl
type
label
HMGA2 exhibits dRP/AP site cle ...... totoxicity during chemotherapy
@ast
HMGA2 exhibits dRP/AP site cle ...... totoxicity during chemotherapy
@en
HMGA2 exhibits dRP/AP site cle ...... totoxicity during chemotherapy
@en-gb
HMGA2 exhibits dRP/AP site cle ...... totoxicity during chemotherapy
@nl
prefLabel
HMGA2 exhibits dRP/AP site cle ...... totoxicity during chemotherapy
@ast
HMGA2 exhibits dRP/AP site cle ...... totoxicity during chemotherapy
@en
HMGA2 exhibits dRP/AP site cle ...... totoxicity during chemotherapy
@en-gb
HMGA2 exhibits dRP/AP site cle ...... totoxicity during chemotherapy
@nl
P2093
P2860
P921
P3181
P356
P1476
HMGA2 exhibits dRP/AP site cle ...... totoxicity during chemotherapy
@en
P2093
Dana Henderson
Heike Summer
Lihong Zhan
Padmapriya Sathiyanathan
Peter Dröge
Sabrina Peter
Steven D Goodman
Thomas Klonisch
P2860
P304
P3181
P356
10.1093/NAR/GKP375
P407
P577
2009-07-01T00:00:00Z